CytomX Therapeutics (NASDAQ:CTMX) posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.13), Fidelity Earnings reports. CytomX Therapeutics had a negative net margin of 163.18% and a negative return on equity of 90.62%. The company had revenue of $10.71 million for the quarter, compared to the consensus estimate of $23.58 million.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Shares of CTMX traded down $0.02 on Friday, hitting $5.36. The company’s stock had a trading volume of 354,200 shares, compared to its average volume of 524,094. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.40 and a quick ratio of 4.40. The company has a market capitalization of $244.44 million, a PE ratio of -2.64 and a beta of 0.64. The company has a 50 day moving average price of $6.76 and a 200 day moving average price of $9.34. CytomX Therapeutics has a fifty-two week low of $5.21 and a fifty-two week high of $19.75.
A number of equities analysts have recently commented on CTMX shares. Zacks Investment Research lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 15th. Wedbush downgraded CytomX Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $25.00 to $8.00 in a research report on Monday, November 11th. Mizuho reaffirmed a “buy” rating and set a $16.00 price objective on shares of CytomX Therapeutics in a report on Monday, August 12th. BidaskClub downgraded CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 1st. Finally, ValuEngine raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $18.25.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Further Reading: Convertible Shares